HUE031581T2 - Betegségek kezelése, amelyek antibiotikumok felhasználásával kapcsolatosak - Google Patents

Betegségek kezelése, amelyek antibiotikumok felhasználásával kapcsolatosak Download PDF

Info

Publication number
HUE031581T2
HUE031581T2 HUE10075449A HUE10075449A HUE031581T2 HU E031581 T2 HUE031581 T2 HU E031581T2 HU E10075449 A HUE10075449 A HU E10075449A HU E10075449 A HUE10075449 A HU E10075449A HU E031581 T2 HUE031581 T2 HU E031581T2
Authority
HU
Hungary
Prior art keywords
compound
antibiotic
difficile
paragraph
vancomycin
Prior art date
Application number
HUE10075449A
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUE031581T2 publication Critical patent/HUE031581T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Claims (2)

V "i* N V\ L· Vsjgj&igf* ggcdpssk Mp fil); :
1¾ íkíksssAifers betegség te?«îésÉPi*w «'.egcsemét·«· jstetes«*·«^ ameiyei (üs&amp;kùiv&amp;-t*iit>£'<m i St&amp;pkyiocociUs eurem (MRSA) pksk&amp;À éism&amp;b&amp;i gp s smîten-rarm'*· ie;hm$àla*àv$i kapcsol«^ vagy ibï ·« beîegèég krftCRerjp»» fett»$*bjUé$àv*S kitp,’SOÎ*îos vagy (&amp;>,$: îvïîepég at»iv<îà»s te?âj>sa fçîîma-sâlimvs} ks-psÄsp â, Vegvîibi AOhwsvOferä ss s. Iggsvpmsi ^e'-'lrs, akO s pkl&amp;ís «s7ôv S> Vegyül«« AObsssMlàm ss I. Îgiüyjiiss^î süwsssîï. ah«!ay&amp;.'i«r..< ernb®r>, *£î 4>: Vegyülő« fçjhivÎOTâlfc« áí: î So^ï:ÎÎ5Îï ; Jssi; Ιί*ρ\·8«ί»ύ>« i&amp;SïÂS*> S. A VőgpífeS &amp;&amp;S*X8áííte &amp; A ielfesàiîssi« s;î K$. eilte Ä* akol § b«i«'gs.t% pS««ck>«i«fS&amp;{S.fS5>S«S «SÍ«»'». 'S 7. A vegyük* Mmxtâïàm'·*! \~i) Ï$i&amp;ypifïmk lïkmiïlyiL· s»e«M< shc-S s:a sOsgííissvlb vsgytlp kíküíkeísí ÍO «tg»#l kürülfedüí j g-% icsiaiOmcsjgyMgfe % Vftgp||*{ ifeitessîxêièâî* 3 ?. «g&amp;ayjjostf sasw, áol At Mágí>k«<tó vagyát«* k«k&amp;bel^:§0^#:Í kliilMOâ 400 ja&amp;*ig í«j«áé s»aav&amp;égô egy***«- v**y két«ef íüttétsO adsgato* aapaafc v#to,
9. A vRjjyßie» feihs«iaàJx>·« a? 1*7. ig&amp;syeoawtk fcfcmefyü» á^ri^í^í;:#* 10 egyft&amp;cn âlka'^iiïÎÎÔi îïêgv stoVaïüg ;Sv,PsS sdsgíOásts k&amp;jwiís vslà, i&amp;. Avbgyuîeï fdhasafiiilteä &amp;<. 1-0, ;gésyp>a?!>k ÍMSíwoíyikí.’ sasiak sííkl S:#||íSMí
k: s vegyid üö-íÖijVs-á!; tamUaasss s íelj^ - ««ftbííxAas snpspss vQTsalk9Xtatv&amp; és s ïïmvM<tfc É&amp;sSk lâSïïUsfïicnï A-bül :4¾ C-F bői áílMk ísíaslvíkask » köv«tk«íü a kíplsíe:
2 , EF
? ν Μ, A vegyőta {«îteïMOx··* s* 1··ΌΧ îgàîypofâtok b&amp;;ndy*ke alfáit, <0x0 à vífcydfctf sdagolSsa s sicSvïïs îîi'iîiïAîj's ösáisxs.» îôrîfisîk. S \t: A vssgyôtef· -s* I-Ή. igAi^stek bfeslyikvsamäil,. klxO a wgÿ&amp;as ápolása <?g>lèl "tikçy aik&amp;Eoâ&amp;g f«r;s>d6efi K&amp;s&amp;jsts k&amp;íwftíá; íutíjöí napig XQíüdyr; tiiíréftiK'- Ifi A 'vggytsleí fdhassjOOssrs s» !·)2, igécypoa-ok bàtsœfcyske ssamt, ahwl s vsg^ûkf· 6§y sm^y. « vegy&amp;k». §û%<âï ysigy !ôôOfe-࣠:)Μμχ a»· lies a»»bî.«sxkm «ay&amp;ps ¥äsiSiköÄ¥S. 10 î; ί. <s* XÍ V' ?5
HUE10075449A 2004-05-14 2005-05-13 Betegségek kezelése, amelyek antibiotikumok felhasználásával kapcsolatosak HUE031581T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
HUE031581T2 true HUE031581T2 (hu) 2017-07-28

Family

ID=35428857

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE10075450A HUE043945T2 (hu) 2004-05-14 2005-05-13 Betegségek kezelése antibiotikumok használatával összefüggésben
HUE09156339A HUE027757T2 (hu) 2004-05-14 2005-05-13 Antibiotikumok használatával kapcsolatos betegségek kezelése
HUE10075449A HUE031581T2 (hu) 2004-05-14 2005-05-13 Betegségek kezelése, amelyek antibiotikumok felhasználásával kapcsolatosak

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE10075450A HUE043945T2 (hu) 2004-05-14 2005-05-13 Betegségek kezelése antibiotikumok használatával összefüggésben
HUE09156339A HUE027757T2 (hu) 2004-05-14 2005-05-13 Antibiotikumok használatával kapcsolatos betegségek kezelése

Country Status (17)

Country Link
US (2) US20070173462A1 (hu)
EP (4) EP2305245B1 (hu)
JP (2) JP5734545B2 (hu)
AT (1) ATE516024T1 (hu)
BR (1) BRPI0511119A (hu)
CA (2) CA2776682A1 (hu)
CY (2) CY1117501T1 (hu)
DK (3) DK2305244T3 (hu)
ES (4) ES2395404T3 (hu)
HU (3) HUE043945T2 (hu)
LT (1) LT2305245T (hu)
MX (2) MXPA06013245A (hu)
PL (3) PL2305245T3 (hu)
PT (2) PT2305245T (hu)
SI (2) SI2070530T1 (hu)
TR (1) TR201902533T4 (hu)
WO (1) WO2005112990A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
MX2007009196A (es) * 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
AU2006304868B2 (en) * 2005-10-21 2013-02-21 Merck Sharp & Dohme Corp. Method of treating clostridium difficile-associated diarrhea
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
WO2009117310A2 (en) * 2008-03-17 2009-09-24 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
WO2011061667A1 (en) * 2009-11-17 2011-05-26 Piramal Life Sciences Limited Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
EP2519108A4 (en) 2009-12-31 2013-10-16 Ira Milton Trachtman COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF INFLAMMATORY INTESTINAL DISEASE
MX2012013374A (es) * 2010-05-18 2013-05-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
TR201815891T4 (tr) 2014-05-09 2018-11-21 Astellas Pharma Europe Ltd Tiakumisin bileşiği için tedavi rejimi.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (hu) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP2005534332A (ja) * 2002-07-29 2005-11-17 オプティマー ファーマシューティカルズ、インコーポレイテッド チアクマイシン生産
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
JP2012197309A (ja) 2012-10-18
EP2305244A1 (en) 2011-04-06
WO2005112990A3 (en) 2006-01-05
BRPI0511119A (pt) 2007-11-27
DK2070530T3 (da) 2016-05-17
SI2305245T1 (sl) 2019-04-30
EP2305245B1 (en) 2019-01-02
ES2713954T3 (es) 2019-05-24
MXPA06013245A (es) 2007-05-09
EP1765312A2 (en) 2007-03-28
US20130274175A1 (en) 2013-10-17
PT2305244T (pt) 2016-12-29
ES2608046T3 (es) 2017-04-05
HUE027757T2 (hu) 2016-11-28
WO2005112990A2 (en) 2005-12-01
ES2395404T3 (es) 2013-02-12
MX344601B (es) 2016-12-20
JP6101010B2 (ja) 2017-03-22
EP2070530B1 (en) 2016-02-17
JP5734545B2 (ja) 2015-06-17
PL2305245T3 (pl) 2019-05-31
LT2305245T (lt) 2019-03-12
PL2305244T3 (pl) 2017-04-28
EP2305245A1 (en) 2011-04-06
CA2566687A1 (en) 2005-12-01
EP1765312B1 (en) 2011-07-13
SI2070530T1 (sl) 2016-05-31
PT2305245T (pt) 2019-03-19
DK2305245T3 (en) 2019-03-25
CY1117501T1 (el) 2017-04-26
US20070173462A1 (en) 2007-07-26
EP1765312A4 (en) 2007-08-22
CY1121284T1 (el) 2020-05-29
CA2566687C (en) 2012-07-24
EP2305244B1 (en) 2016-10-12
HUE043945T2 (hu) 2019-09-30
CA2776682A1 (en) 2005-12-01
EP2070530A1 (en) 2009-06-17
JP2007537290A (ja) 2007-12-20
PL2070530T3 (pl) 2016-06-30
DK2305244T3 (en) 2017-01-30
TR201902533T4 (tr) 2019-03-21
ES2565609T3 (es) 2016-04-05
ATE516024T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
CA2566687C (en) The use of tiacumicin b in the treatment of antibiotic resistant staphylococcus or vancomycin-resistant enterococci infections
JP5166040B2 (ja) １８員大環状化合物及びその類似化合物
EP2222309B1 (en) Antibiotic macrocycle compounds and methods of manufacture and use thereof
EP1545453B1 (en) Rifalazil for treating infections of clostridium difficile
US20040147441A1 (en) Methods and reagents for preventing bacteremias
HUE027373T2 (hu) Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
JP5825217B2 (ja) １８員大環状化合物及びその類似化合物
AU2013245517B2 (en) 18-membered macrocycles and analogs thereof
WO1996008259A1 (en) Synergistic antimicrobial composition